机构:
JICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPANJICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN
MIYAKAWA, Y
[1
]
OKAMOTO, H
论文数: 0引用数: 0
h-index: 0
机构:
JICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPANJICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN
OKAMOTO, H
[1
]
MAYUMI, M
论文数: 0引用数: 0
h-index: 0
机构:
JICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPANJICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN
MAYUMI, M
[1
]
机构:
[1] JICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN
来源:
MOLECULAR MEDICINE TODAY
|
1995年
/
1卷
/
01期
关键词:
D O I:
10.1016/1357-4310(95)80015-8
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Hepatitis C virus (HCV) is the major aetiological agent for blood borne non-A, non-B hepatitis worldwide, Since its discovery in 1989, at least 28 HCV genotypes have been reported, which differ by >20% in the nucleotide sequence of the entire genome (similar to 9500 nucleotides) or the sequence of the E1 gene (576 nucleotides). Different HCV genotypes have distinct geographical distributions, and may be associated with variations in viral replication and disease-inducing activity, as well as poor response to interferons in patients with chronic hepatitis C.